Medpace Hldgs Stock: A Deep Dive Into Analyst Perspectives (9 Ratings)
Analysts' ratings for Medpace Hldgs (NASDAQ:MEDP) over the last quarter vary from bullish to bearish, as provided by 9 analysts.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 1 | 6 | 0 | 2 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 4 | 0 | 2 |
| 3M Ago | 0 | 0 | 1 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $417.89, a high estimate of $510.00, and a low estimate of $300.00. Marking an increase of 37.35%, the current average surpasses the previous average price target of $304.25.
Analyzing Analyst Ratings: A Detailed Breakdown
A clear picture of Medpace Hldgs's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Jamie Clark | Rothschild & Co | Raises | Neutral | $474.00 | $342.00 |
| Dan Leonard | UBS | Raises | Sell | $305.00 | $300.00 |
| Ann Hynes | Mizuho | Raises | Outperform | $510.00 | $328.00 |
| Jailendra Singh | Truist Securities | Raises | Hold | $436.00 | $298.00 |
| Justin Bowers | Deutsche Bank | Raises | Hold | $430.00 | $270.00 |
| Luke Sergott | Barclays | Raises | Equal-Weight | $450.00 | $300.00 |
| Eric Coldwell | Baird | Raises | Neutral | $490.00 | $313.00 |
| Charles Rhyee | TD Cowen | Raises | Sell | $366.00 | $283.00 |
| Luke Sergott | Barclays | Announces | Equal-Weight | $300.00 | - |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Medpace Hldgs. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Medpace Hldgs compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Medpace Hldgs's stock. This examination reveals shifts in analysts' expectations over time.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Medpace Hldgs's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Medpace Hldgs analyst ratings.
Get to Know Medpace Hldgs Better
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
Medpace Hldgs: A Financial Overview
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Medpace Hldgs displayed positive results in 3M. As of 30 June, 2025, the company achieved a solid revenue growth rate of approximately 14.24%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Medpace Hldgs's net margin is impressive, surpassing industry averages. With a net margin of 14.96%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Medpace Hldgs's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 23.57%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 5.2%, the company showcases effective utilization of assets.
Debt Management: Medpace Hldgs's debt-to-equity ratio is below the industry average. With a ratio of 0.72, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Understanding the Relevance of Analyst Ratings
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.